Patients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care
unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity
evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the
benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in
guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory
failure at ICU admission.
Phase:
Phase 4
Details
Lead Sponsor:
Aalborg University Hospital
Collaborators:
Copenhagen Trial Unit, Center for Clinical Intervention Research Rigshospitalet, Denmark